Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Aug

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

ACS Study Quantifies Financial Burden of Cancer in Older Patients

Transplant Consolidation Improves Survival in Primary CNS Lymphoma

Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL

NCI Names New CCR Director

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy